PF-Atlas › Drugs › Pamrevlumab

Pamrevlumab

Idiopathic Pulmonary Fibrosis · Anti-CTGF/CCN2

Clinical trials
4
Mechanism
Anti-CTGF/CCN2
Developer
FibroGen

Overview

Pamrevlumab is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis, acting via anti-ctgf/ccn2. It appears in 4 tracked IPF clinical trials.

Pamrevlumab clinical trials

ZEPHYRUS-2 (Phase 3)NCT04419558 (Phase 3)NCT03955146 (Phase 3)NCT01890265 (Phase 2)

Explore related

Anti-CTGF/CCN2All trialsResearch
Medical disclaimer. This page summarizes research about Pamrevlumab for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.